ZA200601385B - Methods for administering aripiprazole - Google Patents

Methods for administering aripiprazole

Info

Publication number: ZA200601385B
Authority: ZA; South Africa
Prior art keywords: extended release; aripiprazole; methods; injection; administering
Prior art date: 2003-08-06

Application number

ZA200601385A

Other languages

English (en)

Inventor

Brown Josiah

Original Assignee

Alkermes Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-06

Filing date

2006-02-16

Publication date

2007-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34116189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200601385(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-16 Application filed by Alkermes Inc filed Critical Alkermes Inc

2007-02-28 Publication of ZA200601385B publication Critical patent/ZA200601385B/xx

Links

CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 2
229960004372 aripiprazole Drugs 0.000 title abstract 2
238000013265 extended release Methods 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
238000002347 injection Methods 0.000 abstract 2
239000007924 injection Substances 0.000 abstract 2
239000004005 microsphere Substances 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000013543 active substance Substances 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Dispersion Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

ZA200601385A 2003-08-06 2006-02-16 Methods for administering aripiprazole ZA200601385B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/635,221 US20050032811A1 (en)	2003-08-06	2003-08-06	Methods for administering aripiprazole

Publications (1)

Publication Number	Publication Date
ZA200601385B true ZA200601385B (en)	2007-02-28

Family

ID=34116189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200601385A ZA200601385B (en)	2003-08-06	2006-02-16	Methods for administering aripiprazole

Country Status (21)

Country	Link
US (9)	US20050032811A1 (fr)
EP (2)	EP2340810A1 (fr)
JP (3)	JP5300194B2 (fr)
CN (2)	CN1845721A (fr)
AT (1)	ATE522200T1 (fr)
AU (1)	AU2004264886C1 (fr)
CA (1)	CA2534997C (fr)
CY (1)	CY1111874T1 (fr)
DK (1)	DK1660037T3 (fr)
ES (1)	ES2369893T3 (fr)
HR (1)	HRP20110646T1 (fr)
IL (1)	IL173441A (fr)
MX (1)	MXPA06001350A (fr)
NO (1)	NO339816B1 (fr)
NZ (1)	NZ545037A (fr)
PL (1)	PL1660037T3 (fr)
PT (1)	PT1660037E (fr)
SE (1)	SE1660037T5 (fr)
SI (1)	SI1660037T1 (fr)
WO (1)	WO2005016262A2 (fr)
ZA (1)	ZA200601385B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6770478B2 (en) *	2000-02-10	2004-08-03	The Regents Of The University Of California	Erythrocytic cells and method for preserving cells
US20050032811A1 (en) *	2003-08-06	2005-02-10	Josiah Brown	Methods for administering aripiprazole
UA82561C2 (uk) *	2003-10-23	2008-04-25	Оцука Фармасьютикалз Ко., Лтд.	Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
TWI371274B (en) *	2003-10-23	2012-09-01	Bristol Myers Squibb Co	Process for making sterile aripiprazole of desired mean particle size
CA2622758A1 (fr) *	2005-09-15	2007-03-29	Elan Pharma International, Limited	Formulations aripiprazoliques nanoparticulaires
CN103071209A (zh) *	2005-11-17	2013-05-01	周吉尼克斯股份有限公司	用无针注射递送粘稠制剂
US7799790B2 (en)	2006-07-20	2010-09-21	Helm Ag	Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (fr)	2006-07-20	2008-01-23	Helm AG	Aripiprazole amorphe et son procédé de préparation
GB0618879D0 (en) *	2006-09-26	2006-11-01	Zysis Ltd	Pharmaceutical compositions
UA96342C2 (en) *	2007-06-25	2011-10-25	Оцука Фармасьютикал Ко., Лтд.	Microspheres having core/shell structure
SI2170279T1 (en) *	2007-07-31	2018-04-30	Otsuka Pharmaceutical Co., Ltd.	Methods for producing aripiprazole suspension and freeze-dried formulation
US8431576B2 (en)	2009-06-25	2013-04-30	Alkermes Pharma Ireland Limited	Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2937222C (fr) *	2009-06-25	2019-06-04	Alkermes Pharma Ireland Limited	Promedicaments de composes nh acides
ES2691671T3 (es)	2010-06-24	2018-11-28	Alkermes Pharma Ireland Limited	Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
EP2629775A4 (fr) *	2010-10-18	2014-06-11	Dainippon Sumitomo Pharma Co	Formulation à libération prolongée pour injection
AR083884A1 (es) *	2010-11-16	2013-03-27	Otsuka Pharma Co Ltd	Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) *	2010-12-14	2016-09-28	江苏豪森药业集团有限公司	一种持续释放的注射制剂及其制备方法和用途
HUE065359T2 (hu)	2011-03-18	2024-05-28	Alkermes Pharma Ireland Ltd	Szorbitán-észtereket tartalmazó gyógyászati készítmények
JO3410B1 (ar)	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
JP5952912B2 (ja)	2011-12-15	2016-07-13	アルカーメスファーマアイルランドリミテッド	二級アミン化合物のプロドラッグ
CN103301461B (zh) *	2012-03-08	2018-09-07	江苏豪森药业集团有限公司	一种长效注射制剂及其制备方法和用途
ES2950418T3 (es) *	2012-03-19	2023-10-09	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden alcohol bencílico
JP6219918B2 (ja) *	2012-03-19	2017-10-25	アルカームスファーマアイルランドリミテッド	グリセロールエステルを含む医薬組成物
ES2765036T3 (es) *	2012-03-19	2020-06-05	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden esteres de ácidos grasos
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
AR090775A1 (es) *	2012-04-23	2014-12-03	Otsuka Pharma Co Ltd	Preparado inyectable
EP2897592B1 (fr)	2012-09-19	2020-02-19	Alkermes Pharma Ireland Limited	Compositions pharmaceutiques ayant une plus grande stabilité au stockage
US9051268B2 (en)	2013-04-30	2015-06-09	Otsuka Pharmaceutical Co., Ltd.	Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
BR112016021535A8 (pt)	2014-03-20	2021-07-20	Alkermes Pharma Ireland Ltd	kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
CN105078898B (zh) *	2014-05-22	2018-08-28	上海现代药物制剂工程研究中心有限公司	阿立哌唑长效缓释微粒注射剂及其制备方法
RU2705376C2 (ru) *	2014-08-18	2019-11-07	Алкермес Фарма Айэленд Лимитед	Композиции пролекарства арипипразола
MA55917A (fr)	2014-08-25	2022-03-16	Alkermes Pharma Ireland Ltd	Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
CN106474058B (zh)	2015-08-31	2020-01-07	南京诺瑞特医药科技有限公司	具有延长的保质期的阿立哌唑可注射悬浮液制剂
EP3761983A1 (fr)	2018-03-05	2021-01-13	Alkermes Pharma Ireland Limited	Stratégie de dosage d'aripiprazole
CN108498456B (zh)	2018-05-16	2021-01-01	丽珠医药集团股份有限公司	一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) *	2019-08-06	2021-10-22	深圳市泛谷药业股份有限公司	一种阿立哌唑长效注射制剂及其制备方法
US20230310417A1 (en)	2020-03-30	2023-10-05	Cipla Limited	Injectable aripiprazole formulation
HUE069157T2 (hu)	2020-04-01	2025-02-28	Otsuka Pharma Co Ltd	Eljárások aripiprazol kezelések adagoláskezdésére
KR102378590B1 (ko) *	2020-09-28	2022-03-24	(주)위바이오트리	난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN115212174B (zh) *	2022-07-18	2024-02-20	辉粒药业(苏州)有限公司	一种载阿立哌唑长效缓释微球及其制备方法
CN115969785A (zh) *	2022-12-30	2023-04-18	辰欣药业股份有限公司	一种阿立哌唑注射剂及其制备方法
CN120957722A (zh)	2023-04-26	2025-11-14	大塚制药株式会社	用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5832899A (ja)	1981-08-18	1983-02-25	Takeda Chem Ind Ltd	オキセンドロン水性懸濁剤
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
FR2663223B1 (fr)	1990-06-14	1994-12-02	Af Aplicaciones Far Lab	Forme galenique parenterale.
US6294170B1 (en) *	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US7179486B1 (en) *	1997-04-01	2007-02-20	Nostrum Pharmaceuticals, Inc.	Process for preparing sustained release tablets
US6455526B1 (en) *	1998-12-16	2002-09-24	Aventis Pharmaceuticals, Inc.	Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6559128B1 (en) *	2000-01-21	2003-05-06	Northwestern University	Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US6495164B1 (en) *	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
WO2002026726A2 (fr) *	2000-09-26	2002-04-04	The Johns Hopkins University	Compositions antivirales et leurs procedes d'utilisation
DE10048868A1 (de) *	2000-10-02	2002-04-11	Basf Ag	Verfahren und Vorrichtung zur Einmischung von Zusatzstoffen während der Konditionierung von Tierfutter
JP2002191256A (ja)	2000-12-26	2002-07-09	Yoshikatsu Nakajima	水槽
TWI239247B (en) *	2001-06-14	2005-09-11	Otsuka Pharma Co Ltd	Pharmaceutical composition
US7658998B2 (en) *	2003-01-22	2010-02-09	Alkermes Controlled Therapeutics, Inc.	Method of preparing sustained release microparticles
US6987111B2 (en) *	2003-08-06	2006-01-17	Alkermes Controlled Therapeutics, Ii	Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) *	2003-08-06	2005-02-10	Josiah Brown	Methods for administering aripiprazole
UA82561C2 (uk) *	2003-10-23	2008-04-25	Оцука Фармасьютикалз Ко., Лтд.	Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
JO3410B1 (ar) *	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
US10525057B2 (en) *	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
HUE069157T2 (hu) *	2020-04-01	2025-02-28	Otsuka Pharma Co Ltd	Eljárások aripiprazol kezelések adagoláskezdésére

2003
- 2003-08-06 US US10/635,221 patent/US20050032811A1/en not_active Abandoned
2004
- 2004-07-29 WO PCT/US2004/024345 patent/WO2005016262A2/fr not_active Ceased
- 2004-07-29 SI SI200431772T patent/SI1660037T1/sl unknown
- 2004-07-29 JP JP2006522614A patent/JP5300194B2/ja not_active Expired - Lifetime
- 2004-07-29 PT PT04779411T patent/PT1660037E/pt unknown
- 2004-07-29 PL PL04779411T patent/PL1660037T3/pl unknown
- 2004-07-29 HR HR20110646T patent/HRP20110646T1/hr unknown
- 2004-07-29 NZ NZ545037A patent/NZ545037A/en not_active IP Right Cessation
- 2004-07-29 CN CNA2004800252878A patent/CN1845721A/zh active Pending
- 2004-07-29 CA CA2534997A patent/CA2534997C/fr not_active Expired - Lifetime
- 2004-07-29 ES ES04779411T patent/ES2369893T3/es not_active Expired - Lifetime
- 2004-07-29 AT AT04779411T patent/ATE522200T1/de active
- 2004-07-29 EP EP10193459A patent/EP2340810A1/fr not_active Withdrawn
- 2004-07-29 MX MXPA06001350A patent/MXPA06001350A/es active IP Right Grant
- 2004-07-29 SE SE04779411T patent/SE1660037T5/xx unknown
- 2004-07-29 EP EP04779411A patent/EP1660037B1/fr not_active Expired - Lifetime
- 2004-07-29 DK DK04779411.0T patent/DK1660037T3/da active
- 2004-07-29 AU AU2004264886A patent/AU2004264886C1/en not_active Expired
- 2004-07-29 CN CN2011100063238A patent/CN102133171A/zh active Pending
2006
- 2006-01-30 IL IL173441A patent/IL173441A/en active IP Right Grant
- 2006-02-09 NO NO20060638A patent/NO339816B1/no unknown
- 2006-02-16 ZA ZA200601385A patent/ZA200601385B/xx unknown
2008
- 2008-10-15 US US12/251,656 patent/US8338427B2/en not_active Expired - Lifetime
2010
- 2010-08-02 JP JP2010173601A patent/JP5453194B2/ja not_active Expired - Lifetime
2011
- 2011-09-29 CY CY20111100940T patent/CY1111874T1/el unknown
2012
- 2012-03-15 US US13/420,822 patent/US8338428B2/en not_active Expired - Lifetime
- 2012-10-10 US US13/648,544 patent/US8759351B2/en not_active Expired - Lifetime
2013
- 2013-10-10 JP JP2013212864A patent/JP5764634B2/ja not_active Expired - Lifetime
2014
- 2014-01-21 US US14/160,176 patent/US20140275109A1/en not_active Abandoned
2017
- 2017-08-02 US US15/666,840 patent/US20180169005A1/en not_active Abandoned
2018
- 2018-10-22 US US16/166,400 patent/US20190231679A1/en not_active Abandoned
2020
- 2020-12-21 US US17/247,708 patent/US20210346282A1/en not_active Abandoned
2023
- 2023-03-15 US US18/121,883 patent/US20230218506A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20140275109A1 (en)	2014-09-18
EP1660037A4 (fr)	2008-09-24
CN1845721A (zh)	2006-10-11
DK1660037T3 (da)	2011-12-12
SI1660037T1 (sl)	2012-05-31
US20190231679A1 (en)	2019-08-01
US20050032811A1 (en)	2005-02-10
AU2004264886B2 (en)	2007-06-07
PT1660037E (pt)	2011-10-24
CA2534997A1 (fr)	2005-02-24
AU2004264886C1 (en)	2021-06-03
US20090143403A1 (en)	2009-06-04
EP2340810A1 (fr)	2011-07-06
JP2014001250A (ja)	2014-01-09
JP2007501236A (ja)	2007-01-25
HK1091725A1 (en)	2007-01-26
CN102133171A (zh)	2011-07-27
PL1660037T3 (pl)	2012-03-30
SE1660037T5 (fr)	2015-09-15
US8338427B2 (en)	2012-12-25
NZ545037A (en)	2008-10-31
IL173441A0 (en)	2006-06-11
IL173441A (en)	2013-04-30
WO2005016262A2 (fr)	2005-02-24
ES2369893T3 (es)	2011-12-07
EP1660037A2 (fr)	2006-05-31
US20120289516A1 (en)	2012-11-15
HRP20110646T1 (hr)	2011-12-31
US8338428B2 (en)	2012-12-25
US20210346282A1 (en)	2021-11-11
NO20060638L (no)	2006-04-26
ATE522200T1 (de)	2011-09-15
JP5300194B2 (ja)	2013-09-25
NO339816B1 (no)	2017-02-06
AU2004264886A1 (en)	2005-02-24
US20180169005A1 (en)	2018-06-21
WO2005016262A3 (fr)	2005-09-09
JP5764634B2 (ja)	2015-08-19
JP2010248258A (ja)	2010-11-04
JP5453194B2 (ja)	2014-03-26
EP1660037B1 (fr)	2011-08-31
MXPA06001350A (es)	2006-08-23
US8759351B2 (en)	2014-06-24
CA2534997C (fr)	2011-11-01
CY1111874T1 (el)	2015-11-04
US20130090343A1 (en)	2013-04-11
US20230218506A1 (en)	2023-07-13

Publication	Publication Date	Title
ZA200601385B (en)	2007-02-28	Methods for administering aripiprazole
NZ524138A (en)	2004-12-24	Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
DE60327843D1 (de)	2009-07-16	Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
WO2006039704A3 (fr)	2007-11-15	Composition pharmaceutique et methode de traitement d'une arthropathie a capsule articulaire
WO2008131056A3 (fr)	2009-12-03	Préparations monoeximiques a libération soutenue d'analgésiques opioïdes et non opioïdes
PE20050494A1 (es)	2005-08-24	Excipientes en vehiculos de suministro de farmacos
AP2001002264A0 (en)	2001-09-30	Sustained release formulations for growth hormone secretagogues.
WO2008131057A3 (fr)	2009-12-03	Préparations à libération contrôlée d'analgésiques opioïdes et non opioïdes
HUP0105173A2 (hu)	2003-08-28	Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
ZA200800180B (en)	2009-01-28	Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative
MY151468A (en)	2014-05-30	Controlled release solid preparation
BRPI0412364A (pt)	2006-09-05	composição farmacêutica sólida, compreendendo amisulpride
WO2006026592A3 (fr)	2006-09-14	Administration orale de medicaments faiblement absorbes, procedes et compositions associes
PL377683A1 (pl)	2006-02-06	System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
WO2005030132A3 (fr)	2006-10-12	Schemas posologiques therapeutiques pour une administration de combinaisons de medicaments
IL179177A (en)	2013-05-30	A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
EP1634585A4 (fr)	2009-08-12	Microparticule a liberation prolongee contenant un medicament, procede de production correspondant et preparation contenant ladite microparticule
WO2004033484A3 (fr)	2004-06-10	Utilisation de derives stables de la glutamine aux fins d'amelioration de l'absorption medicamenteuse
UA93365C2 (ru)	2011-02-10	Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
EA200701010A1 (ru)	2007-10-26	Препарат гепирона с высокой дозировкой и длительным высвобождением
SG146671A1 (en)	2008-10-30	Therapeutic regimens for administering drug combinations